The Nitrogen In R Is An Amino Nitrogen Attached Indirectly To A Ring By Acyclic Bonding Patents (Class 514/620)
-
Publication number: 20140005179Abstract: The invention provides an oral pharmaceutical composition, optionally in dose unit form, comprising a lipophilic drug substance in dispersion in a physiologically tolerable aqueous carrier, preferably an aqueous gel, wherein said drug substance contains a functional electrostatic group having a pKa value of from 2 to 10, characterised in that said aqueous carrier has a pH at least 0.3 below or above said pKa value, said pH being below said pKa where said group is acidic and above said pKa where said group is basic.Type: ApplicationFiled: April 11, 2011Publication date: January 2, 2014Applicant: AYANDA GROUP ASInventors: Kurt Ingar Draget, Ingvild Haug, Magnus N. Hattrem, Tore Seternes, Steinar Johan Engelsen
-
Patent number: 8609684Abstract: A composition for increasing the bioavailability of Acetaminophen in humans and animals, comprising Acetaminophen, a first water soluble surfactant having a cloud point greater than about 37° C., a second water soluble surfactant having a cloud point greater than about 37° C., wherein a mixture of the first surfactant and the second surfactant comprises a cloud point less than about 37° C.Type: GrantFiled: December 12, 2011Date of Patent: December 17, 2013Assignee: PruGen IP Holdings, Inc.Inventor: Bhiku G. Patel
-
Publication number: 20130317110Abstract: A compound represented by the following General Formula (I): where, in General Formula (I), R1 and R2 each represent an alkyl group which may have a substituent, R3 represents the following General Formula (II) or (III), and R1 and R2 may be identical or different, where, in General Formulas (II) and (III), X represents a hydrogen atom or a halogen atom, R4 represents a methyl group, a dimethyl group or an oxygen atom, and * represents a binding position.Type: ApplicationFiled: May 23, 2013Publication date: November 28, 2013Applicant: FUJITSU LIMITEDInventors: Nozomu Kamiya, Atsushi Tomonaga, Hajime Sugiyama
-
Publication number: 20130317030Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.Type: ApplicationFiled: March 7, 2013Publication date: November 28, 2013Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventor: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
-
Publication number: 20130303568Abstract: The invention is directed to substituted 2-aminoacetamides represented by formula (II): and to pharmaceutically acceptable salts and prodrugs thereof, wherein the substituents are defined herein. The invention is also directed to the use of substituted 2-aminoacetamides in methods for the treatment of neuronal damage following global and focal ischemia, and for the treatment, prevention or amelioration of pain, anxiety, or manic depression, as anticonvulsants, as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.Type: ApplicationFiled: April 22, 2013Publication date: November 14, 2013Inventors: Nancy C. LAN, Yan Wang, Sui Xiong Cai
-
Publication number: 20130289122Abstract: Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly useful for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases.Type: ApplicationFiled: March 11, 2013Publication date: October 31, 2013Inventor: Newron Pharmaceuticals S.P.A.
-
Publication number: 20130274249Abstract: Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly useful for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases.Type: ApplicationFiled: March 11, 2013Publication date: October 17, 2013Inventors: Piero MELLONI, Alessandra Restivo, Emanuela Izzo, Simona Francisconi, Elena Colombo, Cibele Sabido-David
-
Patent number: 8546451Abstract: The present invention relates to methods of treating androgen deprivation therapy (ADT) induced hot flashes and severe hot flashes in a subject.Type: GrantFiled: February 23, 2010Date of Patent: October 1, 2013Assignee: GTx, Inc.Inventors: James T. Dalton, Mitchell S. Steiner, Jeetendra Eswaraka
-
Publication number: 20130253063Abstract: The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.Type: ApplicationFiled: April 2, 2013Publication date: September 26, 2013Applicant: Forest Laboratories Holdings Ltd.Inventors: Anil Chhettry, Murali Divi, Rahul Surana
-
Publication number: 20130244995Abstract: Compounds of general formula (I), their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroidism, pharmaceutical compositions comprising said compounds, and methods of treating diseases with said compounds.Type: ApplicationFiled: November 21, 2011Publication date: September 19, 2013Applicant: LEO PHARMA A/SInventors: Per Vedsø, Lars Kristian Albert Blæhr
-
Patent number: 8530701Abstract: A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]-propanamides and their salts with pharmaceutically acceptable acids with a high degree of purity, i.e. with a content of dibenzyl derivatives impurities lower than 0.03% by weight. The process is carried out by submitting a Schiff base intermediate to a reduction reaction with a reducing agent in an amount of organic solvent to allow the formation (and presence during a substantial portion of the reduction reaction) of a suspension of the Schiff base.Type: GrantFiled: December 1, 2008Date of Patent: September 10, 2013Assignee: Newron Pharmaceuticals, S.p.A.Inventors: Elena Barbanti, Laura Faravelli, Patricia Salvati, Renato Canevotti, Francesco Ponzini
-
Patent number: 8518995Abstract: A method for a prevention and/or treatment of irritable bowel syndrome or amelioration of a symptom thereof in a subject, comprises administering to said subject an effective amount of a compound of formula I:Type: GrantFiled: April 4, 2011Date of Patent: August 27, 2013Assignee: MediciNova, Inc.Inventors: Kazuko Matsuda, Yuichi Iwaki, Kale Ruby
-
Patent number: 8518940Abstract: The present invention embraces compounds selected for interacting with the Fingers-Palm pocket of telomerase and use thereof for modulating the activity of telomerase and preventing or treating diseases or conditions associated with telomerase.Type: GrantFiled: February 8, 2010Date of Patent: August 27, 2013Assignee: The Wistar InstituteInventor: Emmanuel Skordalakes
-
Publication number: 20130210919Abstract: The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described.Type: ApplicationFiled: March 15, 2013Publication date: August 15, 2013Inventor: Forest Laboratories Holdings Ltd.
-
Publication number: 20130210766Abstract: Compositions containing a small molecule therapeutic and an alkyl N,N-disubstituted amino acetate are disclosed. Inclusion of the alkyl N,N-disubstituted amino acetate enhances the pharmacokinetic properties of the small molecule therapeutic.Type: ApplicationFiled: May 4, 2011Publication date: August 15, 2013Applicant: NEXMED HOLDINGS, INC.Inventors: Bassam B. Damaj, Richard Martin
-
Publication number: 20130210778Abstract: This invention relates to a method for the prevention of cardiovascular disease, a formulation for the prevention of cardiovascular disease, the use of specified active principals for the manufacture of such a formulation for use in the method and to a method of preparing said formulation. The formulation of the present invention is a combination of active principals for use in the prevention of cardiovascular disease, notably ischaemic heart disease (including heart attacks) and stroke among the general adult population.Type: ApplicationFiled: March 13, 2013Publication date: August 15, 2013Inventors: Nicholas J. Wald, Malcolm R. Law
-
Patent number: 8481598Abstract: The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.Type: GrantFiled: January 14, 2011Date of Patent: July 9, 2013Inventors: Rahul Surana, Murali Divi, Anil Chhettry
-
Publication number: 20130161222Abstract: This product is made of composition of Paraffin Oil (Kerosene) and 40% Solution of Denatonium Benzoate in EG. The content of Paraffin Oil would be 90% and 10% of 40% Soln. of D. B. E. G. The product can be used with spray bottles in residential and commercial places where Bed Bugs are found. The composition of these three chemicals are capable to eliminate the Bed Bugs and their eggs by applying in the affected area for few weeks or until they are completely eliminated. Normally, these chemical will work as a wonder chemical pesticide very effectively. There is no known side effect of these chemicals.Type: ApplicationFiled: December 21, 2011Publication date: June 27, 2013Inventor: Ajit M. Patel
-
Patent number: 8470831Abstract: Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R?, R?, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.Type: GrantFiled: September 23, 2009Date of Patent: June 25, 2013Assignee: Cogenia SRLInventors: Daniele Fancelli, Mario Varasi, Simon Plyte, Marco Ballarini, Anna Cappa, Giacomo Carenzi, Saverio Minucci, Gilles Pain, Manuela Villa
-
Publication number: 20130150346Abstract: The present disclosure relates to methods of using fatty acid amide hydrolase (FAAH) inhibitors to treat aspects of Parkinson's disease (PD), restless legs syndrome (RLS) and periodic limb movement disorder (PLMD), the use of FAAH inhibitors for the manufacture of medicaments for use in the treatment of PD, RLS and PLMD, as well as pharmaceutically acceptable compositions comprising FAAH inhibitors for use in the treatment of PD, RLS and PLMD.Type: ApplicationFiled: January 7, 2011Publication date: June 13, 2013Applicants: Ironwood Pharmaceutical, Inc.Inventors: James Philip Pearson, Todd G. Milne, Thomas Henry Johnston, Jonathan Michael Brotchie
-
Publication number: 20130143869Abstract: Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction and/or prevention of subcutaneous adipose tissue with improved effectiveness and better reproducible activity.Type: ApplicationFiled: July 14, 2011Publication date: June 6, 2013Applicant: Merz Pharma GmbH & CO. KGaAInventors: Kevin Kiehm, Bernhard Hauptmeier, Harry Abts, Peter Boderke
-
Patent number: 8455550Abstract: The present invention concerns compounds of general formula (1), where in:—-a- is a single or double bond, Ar is an aromatic group, substituted or unsubstituted, R1 and R2 each independently or together are: a hydrogen atom or C1-C6 alkyl group, branched or unbranched, saturated or unsaturated, substituted or unsubstituted; the groups R1 and R2 may also form a heterocycle, R3 and R3? each independently or together are a hydrogen atom or C1-C6 alkyl group, X is an oxygen atom or a sulphur atom, and the addition salts of the compounds of general formula (1) with pharmaceutically acceptable mineral acids or organic acids.Type: GrantFiled: April 2, 2010Date of Patent: June 4, 2013Assignee: Pierre Fabre MedicamentInventors: Stéphane Cuisiat, Adrian Newman-Tancredi, Olivier Vitton, Bernard Vacher
-
Patent number: 8445539Abstract: The disclosure relates to pharmacotherapy of a psychiatric disorder which is schizophrenia and/or anxiety, wherein schizophrenia includes schizophrenia related disorders such as brief psychotic disorders, delusional disorders, schizoaffective disorders, and schizophreniform disorders, and anxiety includes panic disorders, obsessive-compulsive disorders (OCD), post-traumatic stress disorders (PTSD), social phobia or social anxiety disorders, specific phobia, and generalized anxiety disorders (GAD). The compounds of the disclosure are useful for the treatment of the above psychiatric disorders alone or in combination with other therapeutical agents effective in the treatment of schizophrenia and/or anxiety disorders.Type: GrantFiled: June 15, 2010Date of Patent: May 21, 2013Assignee: Newron Pharmaceuticals S.p.A.Inventors: Emanuela Izzo, Laura Faravelli, Elena Barbanti, Patricia Salvati
-
Patent number: 8445513Abstract: The invention relates to the use of certain alpha-aminoamide derivatives in the treatment of RLS and addictive disorders. The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.Type: GrantFiled: April 19, 2005Date of Patent: May 21, 2013Assignee: Newron Pharmaceuticals S.p.A.Inventors: Claudia Besana, Elena Barbanti, Emanuela Izzo, Florian Thaler, Ruggero Fariello, Patricia Salvati, Luca Benatti
-
Publication number: 20130121919Abstract: The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.Type: ApplicationFiled: June 11, 2012Publication date: May 16, 2013Applicant: The Trustees of Columbia University in the City of New YorkInventors: Yan FENG, Mauro Fa, Ottavio Arancio, Shi Xian Deng, Donald W. Landry, Yitshak Francis
-
Publication number: 20130109674Abstract: The present invention relates to, among other things, methods for treating trigeminal cephalgias such as migraine and migraine like headaches and other cerebrovascular conditions associated with pain and or inflammation. When non-steroidal anti inflammatory drugs (NSAIDs), such as ketoprofen, are applied locally using specific topical formulations immediate relief of pain is obtained. Intense pain is typically reduced to mild pain or no pain within 30 minutes of application of the topical formulation. The NSAID may be given in combination with other pharmacological agents, such as vasoconstrictors, opioids, decongestants and/or non-opioid migraine drugs, such as triptans and ergots and agents that affect serotonin receptors as agonists, antagonists or partial agonists.Type: ApplicationFiled: December 17, 2010Publication date: May 2, 2013Applicant: Achelios Therapeutics LLCInventors: Harry J. Leighton, Matthew J. Buderer, Crist J. Frangakis
-
Publication number: 20130072551Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.Type: ApplicationFiled: November 16, 2012Publication date: March 21, 2013Applicant: UNIVERSITE VICTOR SEGALEN - BORDEAUX 2Inventor: Universite Victor Segalen-Bordeaux 2
-
Publication number: 20130072564Abstract: Methods and compositions for activating an EphA receptor can be used for identifying therapeutic agents for cancer.Type: ApplicationFiled: May 1, 2012Publication date: March 21, 2013Inventors: Bingchen Wang, Eugene Myshkin, Hui Miao
-
Publication number: 20130053368Abstract: New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists.Type: ApplicationFiled: August 24, 2012Publication date: February 28, 2013Applicant: Newron Pharmaceuticals S.P.AInventors: Fariello Ruggero, Carlo CATTANEO, Patricia SALVATI, Luca BENATTI
-
Publication number: 20130045969Abstract: The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more strobilurin fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease.Type: ApplicationFiled: March 2, 2011Publication date: February 21, 2013Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: So Kiguchi, Soichi Tanaka, Mayuko Ozawa, Atsushi Iwata
-
Publication number: 20130035296Abstract: The present invention provides a peptide, peptidomimetic or amino acid derivative having a net positive charge of at least +2 and incorporating a disubstituted ? amino acid, each of the substituting groups in the ? amino acid, which may be the same or different, comprises at least (7) non-hydrogen atoms, is lipophilic and has at least one cyclic group, one or more cyclic groups within a substituting group may be linked or fused to one or more cyclic groups within the other substituting group and where cyclic groups are fused in this way the combined total number of non-hydrogen atoms for the two substituting groups is at least (12), for use as a cytolytic therapeutic agent; as well as non therapeutic uses of these molecules and certain defined novel compounds from within this definition.Type: ApplicationFiled: November 2, 2010Publication date: February 7, 2013Applicant: LYTIX BIOPHARMA ASInventors: Morten Strom, Terkel Hansen, Martina Havelkova, Veronika Torfoss
-
Patent number: 8367732Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.Type: GrantFiled: January 11, 2011Date of Patent: February 5, 2013Assignee: Virobay, Inc.Inventors: John O. Link, Craig J. Mossman, Jie Liu, Soon Hyung Woo
-
Publication number: 20120329800Abstract: Administration of a monoamine oxidase inhibitor is useful in the prevention and treatment of muscle dystrophy. Methods and compositions for inhibiting the production of reactive oxygen species in a muscle cell overproducing reactive oxygen species are provided herein.Type: ApplicationFiled: June 22, 2011Publication date: December 27, 2012Inventors: Paolo Bonaldo, Marcella Canton, Fabio DiLisa, Sara Menazza
-
Publication number: 20120295922Abstract: The present invention provides methods for treating and/or preventing mucostitis with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, or compositions comprising the same.Type: ApplicationFiled: May 15, 2012Publication date: November 22, 2012Applicant: POLYMEDIX, INC.Inventors: Richard W. Scott, Bozena Korczak
-
Publication number: 20120295982Abstract: A method of treating a human male patient is disclosed. Enterally administering bedoradrine or a pharmaceutically acceptable salt thereof to a human male patient who is suffering from a medical condition that is responsive to bedoradrine or a pharmaceutically acceptable salt thereof, is useful and benefits human males versus human females. A preferred mode of administration is oral administration.Type: ApplicationFiled: February 21, 2012Publication date: November 22, 2012Inventor: Kirk W. Johnson
-
Patent number: 8309610Abstract: This invention relates to solid crystalline forms of (1RS,3RS,6RS)-6-Dimethylaminomethyl-1-(3-methoxy-phenyl)cyclohexane-1,3-diol hydrochloride (1), methods of producing 1, methods of use of 1, use of 1 as analgesics and pharmaceutical compositions comprising 1.Type: GrantFiled: February 21, 2006Date of Patent: November 13, 2012Assignee: Gruenenthal GmbHInventors: Michael Gruss, Helmut Buschmann, Andreas Fischer, Wolfgang Hell, Dagmar Lischke
-
Publication number: 20120270876Abstract: Methods are provided for treating a subject for a condition caused by an abnormality in the subject's autonomic nervous system. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is pharmacologically modulated with at least one beta-blocker in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, where such conditions include various disease conditions. Also provided are systems and kits for use in practicing the subject methods.Type: ApplicationFiled: April 24, 2012Publication date: October 25, 2012Inventors: Anthony Joonkyoo Yun, Patrick Yuarn-Bor Lee
-
Publication number: 20120264703Abstract: The present invention provides novel methods and formulations for treating anxiety disorders, including Post Traumatic Stress Disorder, in human subjects employing coordinate treatment using ? and ? blockers alone or in combination with additional psychotherapeutic medications to treat the anxiety disorder and reduce symptomology in treated subjects.Type: ApplicationFiled: June 15, 2012Publication date: October 18, 2012Inventors: Arifulla Khan, John Frederick Reinhard, JR.
-
Publication number: 20120264760Abstract: One aspect of the present invention relates to compounds, and pharmaceutically acceptable salts and prodrugs thereof, that are useful as inhibitors of IMPDH. The invention also provides pharmaceutical compositions comprising the compounds of the invention which selectively inhibit parasitic IMPDH. In certain embodiments, the present invention relates to selective inhibition of C. parvum inosine-5?-monophosphate-dehydrogenase over human inosine-5?-monophosphate-dehydrogenase (IMPDH type I and type II). These compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.Type: ApplicationFiled: June 6, 2012Publication date: October 18, 2012Applicants: University of Georgia Research Foundation, Inc., Brandeis UniversityInventors: Lizbeth K. Hedstrom, Boris Striepen
-
Publication number: 20120252792Abstract: The invention provides methods, compositions, and kits for the inhibition of members of the Rho GTPase family. Specifically, the invention provides methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signalling. The invention finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis, inflammation, inflammatory disease), Rho-mediated biological conditions, and in cell signaling research.Type: ApplicationFiled: September 17, 2010Publication date: October 4, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Richard Neubig, Chris Evelyn, Jenny Ryu, Scott Larsen, Jessica Bell
-
Patent number: 8278485Abstract: A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to catalytic hydrogenation in the presence of a heterogeneous catalyst in a protic organic solvent.Type: GrantFiled: November 3, 2011Date of Patent: October 2, 2012Assignee: Newron Pharmaceuticals S.p.A.Inventors: Elena Barbanti, Carla Caccia, Patricia Salvati, Francesco Velardi, Tiziano Ruffilli, Luigi Bogogna
-
Publication number: 20120220592Abstract: 2-Phenylethylamino substituted carboxamide derivatives and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies are presented.Type: ApplicationFiled: January 26, 2012Publication date: August 30, 2012Applicant: Newron Pharmaceuticals S.p.A.Inventors: Florian THALER, Mauro NAPOLETANO, Cibele SABIDO-DAVID, Ermanno MORIGGI, Carla CACCIA, Laura FARAVELLI, Alessandra RESTIVO, Patricia SALVATI
-
Publication number: 20120214852Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.Type: ApplicationFiled: November 8, 2011Publication date: August 23, 2012Applicant: Acucela Inc.Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Feng Hong
-
Publication number: 20120178757Abstract: A method is provided for the prevention of cancer metastasis in a patient comprising administering an adrenergic receptor antagonist to a patient in need thereof. The invention also includes an adrenergic receptor antagonist for use in the prevention of tumour recurrence in a patient. Also provided is a kit of parts for use in such methods comprising an adrenergic receptor antagonist, and an administration vehicle. A method is further included for identifying a patient at risk of developing cancer comprising the step of assaying for levels of expression of adrenergic receptor genes and proteins in said patient.Type: ApplicationFiled: December 8, 2011Publication date: July 12, 2012Applicant: NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUSTInventor: Desmond George Powe
-
Publication number: 20120172426Abstract: The present invention provides novel cycloalkylmethylamine derivatives, and methods of preparing cycloalkylmethylamine derivatives. The present invention also provides methods of using cycloalkylmethylamine derivatives and compositions of cycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.Type: ApplicationFiled: July 1, 2011Publication date: July 5, 2012Applicant: REVIVA PHARMACEUTICALS, INC.Inventors: Laxminarayan Bhat, Kouacou Adiey
-
Publication number: 20120165360Abstract: The invention provides amino- and amido-aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: March 5, 2012Publication date: June 28, 2012Applicant: THERAVANCE, INC.Inventors: Sean G. Trapp, Michael R. Leadbetter, Daniel D. Long, Lan Jiang, Sabine Axt
-
Publication number: 20120142646Abstract: The present invention provides compounds of formula (I) wherein k, Ar, R2, R3, R4, R5, R4?, R5?, R6, R7, A, D, m and E are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: ApplicationFiled: December 19, 2007Publication date: June 7, 2012Inventors: Lilian Alcaraz, Roger Victor Bonnert, Stephen Connolly, Anthony Ronald Cook, Adrian Fisher, Alexander Humphries, Piotr Raubo
-
Publication number: 20120128772Abstract: A controlled release pharmaceutical composition comprising Milnacipran or pharmaceutically acceptable salts thereof and hydrophobic release controlling agent. The composition releases 90% of the total amount of Milnacipran or pharmaceutically acceptable salts thereof between 8 to 20 hours when dissolution is carried out in 900 ml 0.1N HCl, USP apparatus Type I (Basket) at 100 rpm for 2 hrs, followed by 900 ml Phosphate buffer pH 6.8 USP apparatus Type I (Basket) at 100 rpm.Type: ApplicationFiled: August 4, 2010Publication date: May 24, 2012Applicant: LUPIN LIMITEDInventors: Shirish Kumar Kulkarni, Rajesh Kulkani, Pandharinath Jadhav, Ashish Tiwari
-
Publication number: 20120128805Abstract: Disclosed herein are gustatory and/or olfactory aversion compositions comprising one or more bitterants and appropriate adhesives or tackifiers, and the like, which provide a long-lasting effect. The compositions are useful for behavior modification, especially in animals, such as pets or livestock.Type: ApplicationFiled: January 30, 2012Publication date: May 24, 2012Applicant: Vet Planet, LLCInventors: Richard J. Clement, Kati Clement-Frazier
-
Patent number: RE43879Abstract: The present invention concerns the use of a mixture of enantiomers enriched in the dextrogyral enantiomer of milnacipran and/or of at least one of its metabolites, as well as their pharmaceutically-acceptable salts, for the preparation of a drug intended to prevent or to treat disorders that can be managed by double inhibition of serotonin (5-HT) and norepinephrine (NE) reuptake, while limiting the risks of cardiovascular disturbances and/or organ and/or tissue toxicity.Type: GrantFiled: February 27, 2012Date of Patent: December 25, 2012Assignee: Pierre Fabre MedicamentInventors: Jean Deregnaucourt, Richard Grosse